Tallinna Vesi has launched upgrades to improve its customers’ experience today, including a new website, an improved self-service portal and a new visual identity. Aleksandr Timofejev, the CEO of Tallinna Vesi, said that the changes focus on consumers, for whom water services are an integral part of daily life. “Customers have responded very positively to the innovations we’ve introduced so far. For example, over 85% of customers already have a smart meter and have welcomed it as a convenient improvement,” he explained. The company plans to install smart meters for all its customers by the end of this year. Another significant innovation has been the introduction of ice pigging technology in pipe maintenance, which helps to ensure high water quality. The upgraded website www.tallinnavesi.ee offers a variety of information about the water...

Flow Traders appoints Frank Drouet as CEO Asia-Pacific to support regional expansion Amsterdam, the Netherlands — Flow Traders Ltd. (Euronext: FLOW) announces a leadership update in the Asia-Pacific (APAC) region. With immediate effect, Frank Drouet is appointed Chief Executive Officer Flow Traders APAC and joins the firm’s Executive Committee (ExCo). Frank Drouet brings more than three decades of experience in global financial markets, with deep expertise across equity derivatives, volatility trading and institutional markets. Frank spent more than 30 years at Société Générale in various global and regional leadership positions in Trading. He held positions as Global head of Volatility Trading, Head of Equities and Derivatives APAC and Head of Global Markets. More recently, Frank was Deputy Head of Global Markets at Crédit Agricole. He...

Press ReleaseReminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026April 20, 2026 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today reminds holders of the warrants issued in June 2024 as part of the Company’s equity offering with preemptive rights that these warrants will expire on June 20, 2026. June 20 being a Saturday, the last effective date for trading or exercising the warrants will be Friday, June 19, 2026, close of market day. Reminder of the main features of the warrantsListing of the warrants: The warrants are listed on Euronext Growth Paris ISIN code: FR001400QEQ3 Exercise period: from June 21, 2024 to June 19, 2026 (close of market) Exercise parity: 5 warrants give the holder the right to subscribe...

Harvest volumes Q1 2026 (1)Farming Norway 75.5 thousand tonnes  Farming Scotland 20.5 thousand tonnes  Farming Chile 21.0 thousand tonnes  Farming Canada 8.0 thousand tonnes  Farming Ireland 2.0 thousand tonnes  Farming Faroes 3.0 thousand tonnes  Farming Iceland (Arctic Fish) 6.0 thousand tonnes  Total 136.0 thousand tonnes  Harvest volumes of 136 thousand tonnes versus 108 thousand tonnes in Q1 2025 are record-high for a first quarter, equivalent to a growth of 26%. In connection with the presentation of the Q4 2025 results, Mowi guided a total harvest volume of 128k GWT for Q1 2026. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWT). Additional information Operational EBIT for the Group was approx. EUR 221 million in Q1 2026 (NOK 2.52 billion, EURNOK 11.39). Blended farming cost was...

VANCOUVER, British Columbia, April 19, 2026 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today an update on the near-term operational plan related to the fire that occurred in certain areas of the crushing circuit at the Goose Mine in the evening of April 16, 2026, as described in B2Gold’s news release on April 17, 2026. The Company reconfirms that no injuries were reported and no medical treatment was required related to the fire. The Company can also confirm its initial assessment that the fire damage was localized to the crushing circuit area. There was no damage or impact to the mill or power facility. The Goose Mine currently has mobile crushers available at site and the preliminary operational plan is to utilize these mobile crushers to feed crushed ore directly...

ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA. These posters feature three of the Company’s drug candidates, Olverembatinib (HQP1351), a novel BCR-ABL inhibitor; APG-2449, a FAK/ALK/ROS1 triple tyrosine kinase inhibitor; and APG-5918, a PRC2/EED inhibitor. Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, said, “These preclinical findings...

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR)...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department...

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physiciansVANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that KIMMTRAK® (tebentafusp-tebn)...